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We read with great interest the excellent review by Francoz et al.
[1], recently published in the Journal of Hepatology, regarding
the difﬁculties in the accurate assessment of renal function in
patients with cirrhosis. This has become even more important
and necessary in the MELD era. The main message is in keeping
withourprevious review[2], that is that althoughserumcreatinine
(Cr) is a routine laboratory test andwidely acceptedas ameasureof
renal function, it is only an indirect marker of renal function, i.e. of
glomerularﬁltration rate (GFR). Indeed, aproblem,notoften recog-
nized by hepatologists, is that measurement of Cr suffers from a
variety of interferences [3]. In particular, in patientswith cirrhosis,
we have shown that the interference of bilirubin on Cr measure-
ment is a major problem leading to differences in MELD scores
up to seven points when bilirubin is higher than 23.4 mg/dl, i.e.
thosewith thehighestpriority for liver transplantation [3]. Francoz
et al. [1] mentioned that several methods have been developed in
order to overcome this interference, but we have shown that the
problem has not been resolved [3]. Furthermore, using different
methods of measurement leads to further discrepancy in Cr values
[3,4]. Hence, standardisation of laboratory techniques and ‘normal’
valueswould have to be undertaken for all liver transplant units to
avoid systematic biases in MELD-based allocation systems, or
those which incorporate Cr values [4].
Apart from difﬁculties in measurements, it is well recognized
that Cr concentration is inﬂuenced by several factors unrelated to
renal function, such as totalmusclemass. The latter can lead to dis-
crepancies in Cr concentration between individuals with the same
renal function but of different age, race, and sex [5]. This important
issue was not emphasized in this review [1]. In the UNOS database
[6], it has been shown that women were more likely to die on the
waiting list in the post-MELD era, compared to the pre-MELD one,
althoughwomenwere listedwith lowermedianMELDscores, com-
pared tomen (14vs. 15,p < 0.001) [6]. Theseﬁndings are likely tobe
due to the fact thatwomenhave lowerCr for thesamerenal function
(GFR), compared tomen, aswehavepublishedpreviously [7]. Inter-
estingly,we found that correctingCr by equalising theGFR between
men and women resulted in an increase in MELD score by 2 or 3
points in 65% of female LT candidates [7]. Our ﬁndings with gender
inﬂuences onCrmeasurement are also pertinent to ethnicity differ-
ences with a lower GFR for the same Cr value in those of Asian eth-
nicityandconverselyahigherGFR for thoseofAfricandescent.Thus,
a correction factor for gender and ethnicity could be introduced.
Alternatively, theuse of ‘‘true”GFR couldbe considered in order
to eliminate any gender or race bias. Interestingly, Lim et al. [8] in
the same Journal found that GFR (estimated by using 125I-iothala-
mate) was superior to Cr in assessingmortality risk on the waiting
list. Its incorporation in theMELD score (in the place of Cr), led to a
relatively small, but nevertheless, signiﬁcant improvement of dis-
criminative ability of MELD. Unfortunately, Lim et al. [8] did not
evaluate the prognostic impact of MELD-Cr and MELD-GFR scores
in male and female candidates separately. However, directly mea-
sured GFR is expensive and impractical for routine use, and thus,
identiﬁcation of more accurate and clinically applicable serumJournal of Hepatology 2markers for renal function in cirrhosis are necessary and could
remove the bias of Cr in theMELD score. Similar to our conclusions
in our review [2], Francoz et al. [1] suggested cystatin-C as an alter-
native marker of renal function. However, cystatin-C has its own
limitations and we have found that the available data on cysta-
tin-based formulae have poor agreement with ‘‘true” GFR in
patients with cirrhosis [9]. The inaccuracy of these mathematical
equations may be related to the fact that the original cohorts from
which they were derived did not include patients with cirrhosis.
We believe that new equations are needed in patients with cirrho-
sis to reﬂect ‘‘true” GFR as accurately as possible.
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